Who are Hydroxychloroquine + low-dose prednisone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Hydroxychloroquine + Prednisone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hydroxychloroquine-low-dose-prednisone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Hydroxychloroquine + low-dose prednisone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hydroxychloroquine + low-dose prednisone (Hydroxychloroquine + low-dose prednisone) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial + corticosteroid combination. Area: Immunology.

phase 3 Antimalarial + corticosteroid combination Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Hydroxychloroquine + low-dose prednisone (Hydroxychloroquine + low-dose prednisone) — Assistance Publique - Hôpitaux de Paris. Hydroxychloroquine suppresses immune activation and inflammatory responses, while low-dose prednisone provides additional anti-inflammatory and immunosuppressive effects.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Hydroxychloroquine + low-dose prednisone TARGET	Hydroxychloroquine + low-dose prednisone	Assistance Publique - Hôpitaux de Paris	phase 3	Antimalarial + corticosteroid combination
Hydroxychloroquine + Prednisone	Hydroxychloroquine + Prednisone	University of Milano Bicocca	phase 3	Antimalarial + Corticosteroid combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial + corticosteroid combination class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hydroxychloroquine + low-dose prednisone — Competitive Intelligence Brief. https://druglandscape.com/ci/hydroxychloroquine-low-dose-prednisone. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab